Breathing “Thin Air” May Protect Against Parkinson’s

 Will this be enough to prevent your Parkinson's risk from happening? A competent? doctor would know the answer!

Parkinson’s Disease May Have Link to Stroke March 2017 

But this to consider.

Aging Brain More Vulnerable to Even Mild Oxygen Deprivation June 2025 

The latest here:

Breathing “Thin Air” May Protect Against Parkinson’s 

Summary:

A clinical study from São Paulo State University (UNESP) in Brazil demonstrates that intermittent hypoxia, controlled, alternating exposure to low-oxygen air, is safe, does not impair sleep, and improves metabolic and inflammatory biomarkers in individuals with Parkinson’s disease. Published in Parkinsonism & Related Disorders, the trial revealed that a single 39-minute session lowered stress and inflammatory markers while elevating neuroprotective adiponectin and preventing drops in brain-derived neurotrophic factor (BDNF), pointing toward an innovative complementary therapy.

Key Facts:

• Safe Hormetic Exposure: Alternating four 6-minute cycles of 10% oxygen (simulating 5,800 meters altitude) with 5-minute room-air intervals caused no adverse events, insomnia, or sleep disruptions in Parkinson’s patients or healthy controls.
• Anti-Inflammatory Shift: A single intermittent hypoxia session led to temporary reductions in cortisol and pro-inflammatory leptin, alongside a sustained 24-hour surge in anti-inflammatory adiponectin.
• Neurotrophic Preservation: While resting in normal air resulted in a standard decline in BDNF levels, intermittent hypoxia preserved circulating BDNF concentrations without increasing pro-inflammatory interleukin-6 (IL-6) or altering blood iron balance.

Source: São Paulo State University (UNESP) / FAPESP

Parkinson’s disease affects an estimated 11 million people globally, recognized clinically by the progressive loss of dopaminergic neurons in the substantia nigra that leads to classic motor signs: resting tremor, bradykinesia, postural instability, and rigidity. Yet beyond motor deficits, individuals face debilitating non-motor burdens, including metabolic disruption, systemic neuroinflammation, and persistent sleep disorders that standard dopamine-replacement medications fail to resolve.

Currently, structured physical exercise remains the only non-pharmacological strategy proven to stimulate restorative metabolic and neurotrophic changes in patients.

Now, researchers at São Paulo State University (UNESP) in Brazil, supported by the São Paulo Research Foundation (FAPESP), have uncovered a complementary physical approach: intermittent hypoxia.

Publishing in the journal Parkinsonism & Related Disorders, the team demonstrated that short, carefully metered intervals of breathing simulated high-altitude thin air activate protective cellular defenses in people with Parkinson’s disease without compromising nocturnal sleep or causing adverse reactions.

Harnessing Hormesis: The Science of Controlled Stress

Breathing thin air at high mountain summits is notoriously taxing, frequently triggering acute mountain sickness marked by nausea, headaches, and physical exhaustion. However, when delivered in brief, intermittent bursts, low oxygen operates through “hormesis”, the biological principle where mild, non-damaging cellular stress triggers robust adaptive and protective pathways.

“The initial results indicate that the technique activates protective mechanisms that can safely benefit people with Parkinson’s disease without causing adverse effects. That’s important because it allows us to conduct studies with a larger number of volunteers and with long-term protocols that evaluate the effects of repeated sessions,” said Fabio Barbieri, PhD, head of the Human Movement Research Laboratory (MOVI-LAB) and coordinator of the “Ativa Parkinson” program at UNESP Bauru.

The clinical trial evaluated 30 adult participants, 15 individuals diagnosed with Parkinson’s disease and 15 healthy age-matched controls.

During the 39-minute experimental protocol, participants wore specialized breathing masks that alternated between four 6-minute blocks of hypoxic air (10% oxygen, physiologically equivalent to an altitude of 5,800 meters) separated by three 5-minute normoxic recovery periods (21% room oxygen). On a separate visit, subjects completed a sham control session breathing standard room air throughout.

Resetting Metabolic and Neuroinflammatory Biomarkers

Blood analyses immediately following the session revealed rapid systemic recalibrations in participants with Parkinson’s:

• Hormonal Regulation: The protocol elicited significant transient drops in circulating cortisol, the primary stress hormone, as well as leptin, an adipose hormone that drives neuroinflammatory cascades when elevated.
• Adiponectin Surge: Levels of adiponectin, an endogenous metabolic factor with potent anti-inflammatory and vascular actions that is chronically suppressed in Parkinson’s, increased significantly and remained elevated for up to 24 hours.
• Preserving BDNF: While sitting inactive in normal room air led to an anticipated drop in circulating brain-derived neurotrophic factor (BDNF), a master protein governing neuronal survival and synaptic plasticity, intermittent hypoxia completely arrested this decline.

Crucially, the intervention proved safe. It did not alter systemic iron homeostasis or elevate the pro-inflammatory cytokine interleukin-6 (IL-6), eliminating concerns that hypoxia might provoke systemic inflammation.

“Maintaining stable BDNF levels is a significant finding, as that protein typically declines during periods of physical inactivity – a decline that occurred when patients underwent the control session breathing normal air. Intermittent hypoxia prevented that decline while increasing adiponectin, paving the way for further research,” said first author Murilo Henrique Faria.

Sleep Safety and Mitochondrial Sensors

A critical question was whether exposing patients to low oxygen would trigger nocturnal sleep disturbances or central sleep apneas. Objective sleep monitoring revealed zero disruptions: participants experienced no increase in nighttime awakenings or sleep onset latency.

Co-author Carlos Augusto Kalva-Filho, PhD, explains that the therapeutic benefit is driven by hypoxia-inducible factor 1-alpha (HIF-1alpha). This intracellular transcription factor acts as an oxygen sensor, coordinating mitochondrial bioenergetics and antioxidant defenses when activated by brief oxygen dips.

“It’s that precise control that generates the benefit. So, it isn’t just a matter of fleeing to the mountains,” Kalva-Filho emphasized, noting that prolonged, continuous exposure at high altitudes overburdens tissues, whereas laboratory-controlled cycles trigger cellular repair.

While a single session demonstrated safety and acute biochemical improvements, the researchers stress that intermittent hypoxia is not a cure or replacement for standard dopaminergic drugs. The team is now planning multi-week clinical trials to evaluate whether repeated sessions can produce cumulative motor, cognitive, and sleep improvements in Parkinson’s disease.

Editorial Notes:

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by our staff.

About this Parkinson’s disease Research:

• Media Contact: Heloisa Reinert
• Source: FAPESP
• Image Credit: Image credited to Neuroscience News
• Original Research is Open Access: Parkinsonism & Related Disorders (Oct 1, 2026). “The acute effects of a single session of intermittent hypoxia on blood biomarker concentrations and sleep parameters in people with Parkinson’s disease: A randomized, double-blind, crossover trial.” Authors: Murilo Henrique Faria, Carlos Augusto Kalva-Filho, Vinicius Oliveira Queiroz, Tjeerd W. Boonstra, Marcela de Oliveira, Jônatas Augusto Cursiol, Christian Schlenstedt, Fabio Santos Lira, Barbara Moura Antunes, and Fabio Augusto Barbieri.
• DOI: 10.1016/j.parkreldis.2026.108922